'''Prazepam''' is a [[benzodiazepine]] [[Derivative (chemistry)|derivative]] [[drug]] developed by Warner-Lambert in the 1960s.<ref>US Patent 3192199 – Process for the production of I-CYCLO- ALKYL derivatives of I,X-BENZODIAZEPINE</ref> It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties.<ref>{{cite journal |vauthors=Shader RI, Greenblatt DJ |title=Benzodiazepines: some aspects of their clinical pharmacology |journal=Ciba Found. Symp. |volume=1979 |issue=74 |pages=141–55 |year=1979 |pmid=45081 |doi= |url=}}</ref> Prazepam is a [[prodrug]] for [[desmethyldiazepam]] which is responsible for the therapeutic effects of prazepam.<ref>{{cite journal |vauthors=Jacqmin P, Ansseau M |title=Comparison of sublingual and oral prazepam in normal subjects. II. Pharmacokinetic and pharmacodynamic data |journal=Neuropsychobiology |volume=19 |issue=4 |pages=186–91 |year=1988 |pmid=2854609 |doi= 10.1159/000118458|url=}}</ref>

 
Prazepam is indicated for the short-term treatment of [[anxiety]]. After short-term therapy, the dose is usually gradually tapered-off to reduce or avoid any [[Drug withdrawal|withdrawal]] or [[rebound effects]].<ref>{{cite journal  |vauthors=Rickels K, Sablosky L, Silverman H, etal |title=Prazepam in anxiety: a controlled clinical trial |journal=Compr Psychiatry |volume=18 |issue=3 |pages=239–49 |year=1977 |pmid=858240 |doi= 10.1016/0010-440X(77)90018-9|url=http://linkinghub.elsevier.com/retrieve/pii/0010-440X(77)90018-9}}</ref><ref>{{cite journal |vauthors=Ansseau M, Von Frenckell R |title=(title in French) |trans_title=Value of prazepam drops in the brief treatment of anxiety disorders |language=French |journal=Encephale |volume=17 |issue=4 |pages=291–294 |year=1991 |pmid=1959497 |doi= |url=}}</ref> [[Desmethyldiazepam]], an [[active metabolite]], has a very long half-life of 29 to 224 hours, which contributes to the therapeutic effects of prazepam.<ref>{{cite journal |vauthors=Breimer DD, Jochemsen R, von Albert HH |title=Pharmacokinetics of benzodiazepines. Short-acting versus long-acting |journal=Arzneimittelforschung |volume=30 |issue=5a |pages=875–81 |year=1980 |pmid=6106488 |doi= |url=}}</ref><ref>{{cite journal |vauthors=Allen MD, Greenblatt DJ, Harmatz JS, Shader RI |title=Desmethyldiazepam kinetics in the elderly after oral prazepam |journal=Clin. Pharmacol. Ther. |volume=28 |issue=2 |pages=196–202 |date=August 1980 |pmid=6772370 |doi= 10.1038/clpt.1980.150|url=}}</ref>

 
== Side effects ==

 
Side effects of prazepam are less profound than with other [[benzodiazepines]].<ref>{{cite journal |vauthors=Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI |title=Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo |journal=Clin. Pharmacol. Ther. |volume=44 |issue=3 |pages=326–34 |date=September 1988 |pmid=3138056 |doi= 10.1038/clpt.1988.158|url=}}</ref> Excessive [[drowsiness]] and with longer-term use, [[drug dependence]], are the most common side effects of prazepam.<ref>{{cite journal  |vauthors=Danion JM, Brion S, Escande M, etal |title=(title in French) |trans_title=Treatment of anxiety with prazepam, 40 mg. A controlled study versus lorazepam |language=French |journal=Encephale |volume=10 |issue=3 |pages=135–138 |year=1984 |pmid=6389091 }}</ref><ref>{{cite journal |vauthors=Dièye AM, Sy B, Diarra M, Faye B |title=(title in French) |trans_title=Prescription and use of benzodiazepins in Saint-Louis in Senegal: patient survey |language=French |journal=Ann Pharm Fr |volume=62 |issue=2 |pages=133–137 |date=March 2004 |pmid=15107731 |doi= |url=http://www.masson.fr/masson/MDOI-APF-03-2004-62-2-0003-4509-101019-ART9}}</ref> Side effects such as [[fatigue (medical)|fatigue]] or "feeling spacey" can also occur but less commonly than with other benzodiazepines. Other side effects include feebleness, clumsiness or [[lethargic]], clouded thinking and mental slowness.<ref>{{cite journal |vauthors=Shader RI, Pary RJ, Harmatz JS, Allison S, Locniskar A, Greenblatt DJ |title=Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam |journal=J Clin Psychiatry |volume=45 |issue=10 |pages=411–3 |date=October 1984 |pmid=6148339 |doi= |url=}}</ref><ref>{{cite journal |vauthors=Ansseau M, von Frenckell R, Jacqmin P |title=Comparison of sublingual and oral prazepam in normal subjects. I. Clinical data |journal=Neuropsychobiology |volume=18 |issue=2 |pages=77–82 |year=1987 |pmid=3330182 |doi= 10.1159/000118397|url=}}</ref><ref>{{cite journal |vauthors=Chabannes JP, Lemoine P |title=(title in French) |trans_title=Prazepam drops versus 10 mg prazepam tablets in anxious patients in ambulatory care |language=French |journal=Therapie |volume=45 |issue=6 |pages=467–470 |year=1990 |pmid=2080484 |doi= |url=}}</ref>

 
Prazepam exerts its therapeutic effects primarily via modulating the [[benzodiazepine receptor]] which in turn enhances [[GABA]] function in the brain.<ref name="pmid6114911">{{cite journal |author=Quast U |title=(title in German) |trans_title=Molecular mechanism of action of benzodiazepines |language=German |journal=Fortschr. Med. |volume=99 |issue=20 |pages=788–94 |date=May 1981 |pmid=6114911 |doi= |url=}}</ref> Prazepam like other benzodiazepines has [[anticonvulsant]] properties, but its anticonvulsant properties are not as potent as other benzodiazepines when tested in animal studies.<ref>{{cite journal |vauthors=De Sarro G, Gitto R, Rizzo M, Zappia M, De Sarro A |title=1,4-Benzodiazepine derivatives as anticonvulsant agents in DBA/2 mice |journal=Gen. Pharmacol. |volume=27 |issue=6 |pages=935–41 |date=September 1996 |pmid=8909973 |doi= 10.1016/0306-3623(95)02147-7|url=http://linkinghub.elsevier.com/retrieve/pii/0306362395021477}}</ref><ref>{{cite journal |vauthors=De Sarro G, Chimirri A, Zappala M, Guisti P, Lipartiti M, De Sarro A |title=Azirino&#91;1, 2-d&#93;&#91;1, 4&#93;benzodiazepine derivatives and related 1,4-benzodiazepines as anticonvulsant agents in DBA/2 mice |journal=Gen. Pharmacol. |volume=27 |issue=7 |pages=1155–1162 |date=October 1996 |pmid=8981061 |doi= 10.1016/S0306-3623(96)00049-3|url=http://linkinghub.elsevier.com/retrieve/pii/S0306362396000493}}</ref><ref>{{cite journal |vauthors=De Sarro G, Chimirri A, McKernan R, Quirk K, Giusti P, De Sarro A |title=Anticonvulsant activity of azirino&#91;1,2-d&#93;&#91;1,4&#93;benzodiazepines and related 1,4-benzodiazepines in mice |journal=Pharmacol. Biochem. Behav. |volume=58 |issue=1 |pages=281–289 |date=September 1997 |pmid=9264104 |doi= 10.1016/S0091-3057(96)00565-5|url=http://linkinghub.elsevier.com/retrieve/pii/S0091-3057(96)00565-5}}</ref><ref>{{cite journal |vauthors=Fukinaga M, Ishizawa K, Kamei C |title=Anticonvulsant properties of 1,4-benzodiazepine derivatives in amygdaloid-kindled seizures and their chemical structure-related anticonvulsant action |journal=Pharmacology |volume=57 |issue=5 |pages=233–241 |date=November 1998 |pmid=9742288 |doi= 10.1159/000028247|url=http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=pha57233}}</ref>

 
Prazepam may interact with [[cimetidine]].<ref>{{cite journal |vauthors=Ruffalo RL, Thompson JF, Segal J |title=Cimetidine-benzodiazepine drug interaction |journal=Am J Hosp Pharm |volume=38 |issue=9 |pages=1365–1366 |date=September 1981 |pmid=6116430 |doi= |url=}}</ref> [[Ethanol|Alcohol]] in combination with prazepam increases the adverse effects, particularly performance impairing side effects and [[drowsiness]].<ref>{{cite journal |vauthors=Girre C, Hirschhorn M, Bertaux L, Palombo S, Fournier PE |title=Comparison of performance of healthy volunteers given prazepam alone or combined with ethanol. Relation to drug plasma concentrations |journal=Int Clin Psychopharmacol |volume=6 |issue=4 |pages=227–238 |year=1991 |pmid=1816280 |doi= 10.1097/00004850-199100640-00004|url=}}</ref>

 
* [[Long-term effects of benzodiazepines]]
